HIV Articles
Back
	Islatravir (+doravirine), nucleoside-sparing, oral daily and long-acting new ART regimens; Monthly PrEP; Weekly (NNRTI), Weekly with Lenacapavr       • Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results From Two Phase 3 Randomized, Active-Controlled Studies in Adults Living With HIV-1 - (10/23/25)   • Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) After ISL Dose Reduction From 0.75 mg: Week 48 Results From an Open-Label Phase 3 Study - (10/23/25)   • Switching to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily Maintains Viral Suppression Through Week 48 in the Presence of Archived NNRTI Resistance-Associated Mutations and/or M184I/V in Proviral DNA - (10/23/25)   • Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-Cell Counts in People Living With HIV - (10/23/25)   • Population Pharmacokinetic Analysis of Islatravir and the Impact of Intrinsic Factors in Participants With HIV-1 - (10/23/25)   • Oral Weekly Islatravir + Lenacapavir, Efficacy, PK- Update - (10/27/25)   • Phase 2 Once-Weekly Dose Optimization for Ulonivirine in Combination with Islatravir 2 mg   • Safety and Pharmacokinetics of MK-8527 Oral Once-Monthly: A Phase 2 Study in Adults at Low Risk of HIV-1 Exposure, oral   Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection   The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for DOR/ISL for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen and has set a target action date of April 28, 2026, for the application under the Prescription Drug User Fee Act (PDUFA).   Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection             View Older Articles   Back to Top   www.natap.org